Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Study examines low-risk cannabis use years after legalization

19

Feb 2026

Study examines low-risk cannabis use years after legalization

A new study led by Marie-Pierre Sylvestre, professor at the Université de Montréal School of Public Health, examines cannabis use 4 to 5 years after Canadian legalization by adopting a different perspective: rather than focusing solely on at-risk cases or those associated with problems, it identifies the socio-demographic, mental health, and lifestyle profiles of those who present a low risk of cannabis use disorder (CUD).

Neighborhood poverty, uninsured status linked to COPD hospitalizations

19

Feb 2026

Neighborhood poverty, uninsured status linked to COPD hospitalizations

Certain neighborhood characteristics, including higher poverty, more uninsured residents, and lower educational attainment, may lead to an increase in COPD-related emergency department visits and hospitalizations, according to a new study in the January 2026 issue of Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation, a peer-reviewed, open access journal.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.